AboLiSh study demonstrates clinical benefit of injection guidance when treating spasticity with abobotulinumtoxinA 19th January, 2024: Ipsen has announced top line results from its real-world AboLiSh study (NCT04050527), presented at the 7th international TOXINS conference in Berlin, Germany. The study evaluated utilisation and effectiveness of Dysport® (abobotulinumtoxinA) in people living with lower-limb spasticity and found…
Category: Industry News
Dravet Syndrome and SCN1A-related epilepsies
New study aims to transform understanding The ‘SCN1A Horizons Natural History Study’ is anticipated to be a milestone in transforming understanding of SCN1A epilepsies, including Dravet Syndrome, one of the most complex and severe developmental and epileptic conditions. The nationwide study aims to define the seizure, neurodevelopmental, and behavioural characteristics of SCN1A-related epilepsies in 400…
Increase Rehabilitation Time for Stroke Patients – NICE
The amount of rehabilitation time offered to adults in England who have had a stroke should be significantly increased from previous recommendations, the National Institute for Health and Care Excellence (NICE) said. Previous guidance from 2013 recommended initially offering at least 45 minutes of relevant stroke rehabilitation therapy for a minimum of 5 days per…
Janssen is a proud sponsor of the ABN-INA joint meeting
Janssen is proud to have sponsored the recent ABN-INA joint meeting in Belfast. We recognise the educational impact of events like these, and are grateful to the delegates who attended our lunchtime symposium on Wednesday 10th on the topic of ‘How can brain volume measures inform clinical practice? What have we learned from multiple sclerosis?’…
Parliamentary ABI reception attracts hundreds of attendees
UKABIF trustees and members attended an Acquired Brain Injury reception in Parliament hosted by Chris Bryant MP. Around 60 MPs from across the House attended to hear first hand from people living with an acquired brain injury, just what improvements need to be made. It was a wonderful opportunity for organisations to network and for…
THN391 – First in-human dosing in phase 1 trial in Alzheimer’s disease
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease THN391 binds to the inflammation-driving component of fibrin that is known to activate pathological immune responses in neurodegenerative and ophthalmologic diseases. Based on preclinical studies to date, targeting this region does not impact or diminish fibrin’s critical…
Acute migraine treatment accepted for use on NHS in Scotland
9th May, 2023: Pfizer Ltd announced that the Scottish Medicines Consortium (SMC) has accepted Vydura ® (rimegepant) for restricted use for the treatment of acute migraine with or without aura, for patients who have had inadequate symptom relief after trials of at least two triptans or in whom triptans are contraindicated or not tolerated; and…
Gene in the brain can reduce anxiety in animal model
A gene in the brain driving anxiety symptoms has been identified by an international team of scientists. Modification of the gene is shown to reduce anxiety levels, offering a novel drug target for anxiety disorders. The discovery, led by researchers at the Universities of Bristol and Exeter, was published online online on 25th April in Nature…
Powerful AI algorithm to gain new insights into deadly glioblastoma
Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, US collaborating with international researchers, have developed a sophisticated AI algorithm that performs advanced computational analysis to identify potential therapeutic targets for glioblastoma multiforme (GBM) and other cancers. Their research is described in the Feb. 2 issue of the journal…
